Latest Articles
Addition of Pembrolizumab to Chemotherapy Continues to Demonstrate Overall Survival Benefit in Advanced or Recurrent Endometrial Cancer - The ASCO Post
Addition of Pembrolizumab to Chemotherapy Continues to Demonstrate Overall Survival Benefit in Advanced or Recurrent Endometrial Cancer The ASCO Post
Published: June 3, 2026, 2:49 p.m.
NRG-GY018 at ASCO 2026: Pembrolizumab Plus Chemotherapy Sustains Overall Survival Benefit in Advanced Endometrial Cancer - Oncodaily
NRG-GY018 at ASCO 2026: Pembrolizumab Plus Chemotherapy Sustains Overall Survival Benefit in Advanced Endometrial Cancer Oncodaily
Published: June 3, 2026, 3:15 a.m.
MGST3 Promotes Endometriosis Progression by Suppressing Ferroptosis.
Endometriosis (EMs) is characterized by dysregulated persistence and enhanced invasiveness of ectopic endometrial cells. Current treatment strategies remain limited by high recurrence rates and considerable adverse effects. Although iron overload …
Published: June 3, 2026, midnight
Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer - MSN
Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer MSN
Published: June 2, 2026, 12:41 a.m.
Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer - Medical Xpress
Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer Medical Xpress
Published: June 1, 2026, 8 p.m.
FOCL: Robotic focal therapy platform drives rapid growth, clinical adoption, and expansion into new indications - TradingView
FOCL: Robotic focal therapy platform drives rapid growth, clinical adoption, and expansion into new indications TradingView
Published: June 1, 2026, 6:25 p.m.
FOCL: Robotic focal therapy drives rapid growth, expanding into new indications and global markets - TradingView
FOCL: Robotic focal therapy drives rapid growth, expanding into new indications and global markets TradingView
Published: June 1, 2026, 4:35 p.m.
Dostarlimab Plus Chemo May Offer Cure to Some Advanced Endometrial Cancer Patients - Cancer Therapy Advisor
Dostarlimab Plus Chemo May Offer Cure to Some Advanced Endometrial Cancer Patients Cancer Therapy Advisor
Published: May 30, 2026, 4 a.m.
Pembrolizumab combination therapy improves survival in recurrent endometrial cancer patients - News-Medical
Pembrolizumab combination therapy improves survival in recurrent endometrial cancer patients News-Medical
Published: May 30, 2026, 2:16 a.m.
Pembrolizumab Plus Chemotherapy Shows Sustained Survival in Advanced EC - CancerNetwork
Pembrolizumab Plus Chemotherapy Shows Sustained Survival in Advanced EC CancerNetwork
Published: May 30, 2026, 12:40 a.m.
Link copied to clipboard!